Trial reportFrontiers in medicine2026
Comparative efficacy of Shatavari Ghrita eye drops with Shatavari Ksheerapaka versus Triphala Ghrita eye drops with Shatavari Ksheerapaka in postmenopausal ocular surface disease: a randomized, single-blind trial.
Trial report in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ayurvedic management of Non-Sjögren's Dry Eye (Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Dry eye disease (DED) commonly affects postmenopausal women due to hormonal changes that disrupt tear film homeostasis. In Ayurveda, this stage corresponds to Vardhakya (aging), characterized by Vata predominance and Dhatu Kshaya (tissue depletion), making DED comparable to Shushkakshipaka, a Vata-dominant ocular disorder explained in Netra Roga. This study compared the efficacy of Shatavari Ghrita eye drops and Triphala Ghrita eye drops, each administered with systemic Shatavari Ksheerapaka for mild-to-moderate postmenopausal DED. Methods: The study was a randomized, single-blind, active-controlled superiority trial that included 120 postmenopausal women aged 45-65 years with clinically diagnosed mild-to-moderate DED. Participants were randomly allocated (1:1) into two groups ( Results: Both groups exhibited significant improvements from baseline in subjective symptoms and objective tear film parameters. Compared with Triphala Ghrita, Shatavari Ghrita produced significantly greater improvement in the OSDI (between-group Conclusion: Shatavari Ghrita eye drops, administered with systemic Shatavari Ksheerapaka, were more effective than Triphala Ghrita eye drops in improving dry eye symptoms, tear secretion, and tear film stability in postmenopausal women with mild-to-moderate DED. These findings support Shatavari Ghrita as a promising Ayurvedic therapeutic option for the management of postmenopausal dry eye disease. Clinical Trial Registration: CTRI/2023/06/054213.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.